Sapiens International (NASDAQ:SPNS) vs. Enfusion (NYSE:ENFN) Head-To-Head Survey

Sapiens International (NASDAQ:SPNS) and Enfusion (NYSE:ENFN) are both computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Volatility & Risk

Sapiens International has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Enfusion has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations for Sapiens International and Enfusion, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sapiens International	1	0	2	0	2.33
Enfusion	3	2	1	0	1.67

Sapiens International presently has a consensus target price of $41.67, suggesting a potential upside of 11.86%. Enfusion has a consensus target price of $9.33, suggesting a potential upside of 7.03%. Given Sapiens International’s stronger consensus rating and higher possible upside, analysts plainly believe Sapiens International is more favorable than Enfusion.

Earnings & Valuation

This table compares Sapiens International and Enfusion”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sapiens International	$532.61 million	3.90	$62.44 million	$1.22	30.53
Enfusion	$188.35 million	5.94	$6.03 million	$0.04	218.00

Sapiens International has higher revenue and earnings than Enfusion. Sapiens International is trading at a lower price-to-earnings ratio than Enfusion, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

30.7% of Sapiens International shares are owned by institutional investors. Comparatively, 81.1% of Enfusion shares are owned by institutional investors. 16.0% of Sapiens International shares are owned by company insiders. Comparatively, 36.4% of Enfusion shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Sapiens International and Enfusion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sapiens International	12.92%	17.60%	11.59%
Enfusion	1.98%	6.17%	4.51%

Summary

Sapiens International beats Enfusion on 10 of the 14 factors compared between the two stocks.

About Sapiens International

Sapiens International Corporation N.V. provides software solutions for the insurance industry in North America, the United Kingdom, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company provides various solutions for property and casualty commercial and personal lines, life and pensions, and reinsurance fields. It offers IDITSuite, an AI powered, end-to-end insurance software; DigitalSuite, a cloud-native, future-proof digital engagement platform; IDITGo, a pre-configured, data-enriched insurance launch and accelerator platform solutions; consultancy services for property and casualty commercial lines; and Tia Enterprise solution for customer engagement. The company also provides CoreSuite, an end-to-end cloud and digital PAS for individual and group products across life, health, wealth, and pensions; CustomerConnect, a dynamic self-service and persona-based portal to engage with insureds; AgentConnect, a portal for agents and brokers to focus on sales enablement, customer retention, and increasing customer value; and ReinsuranceMaster, a reinsurance automation software that provides insurers full financial control and flexibility over their entire reinsurance process. The company was founded in 1982 and is headquartered in Holon, Israel.

About Enfusion

Enfusion, Inc. provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines. It also offers Accounting/General Ledger System, a real-time accounting book of record for chief financial officers, chief operating officers, accountants, and operations teams; Enfusion Analytics System, which enables CIOs, portfolio managers, traders, and analysts to analyze portfolios through time horizons and automate customized visualized reports for internal and external stakeholders; and technology-powered and managed services. Enfusion, Inc. was founded in 1997 and is headquartered in Chicago, Illinois.